Evercore ISI analyst Gavin Clark-Gartner downgraded Rocket Pharmaceuticals (RCKT) to In Line from Outperform with a $5 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RCKT:
- Rocket Pharmaceuticals downgraded to Neutral from Overweight at JPMorgan
- Rocket Pharmaceuticals price target lowered to $19 from $51 at Scotiabank
- Broadcom, Arista Networks initiated: Wall Street’s top analyst calls
- Goldman downgrades Rocket to Sell on ‘surprising and concerning’ update
- Rocket Pharmaceuticals downgraded to Sell from Neutral at Goldman Sachs